Physician profile
William Lee
NPI 1174082358
$2,800.90
in general payments reported to CMS, 2019-2025
20 companies · $729 in 2025
The $729 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $169 · 2023: $387 · 2024: $1,516 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $650.15 | 2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $451.22 | 2023-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $343.12 | 2023-2025 | Belbuca, Xtampza |
| Organogenesis INC. | $221.72 | 2025 | Simplimax |
| Globus Medical, INC. | $207.26 | 2025 | Senza, Omnia, Vyrsa V1 |
| Virtus Pharmaceuticals LLC | $204.87 | 2023-2025 | Levorphanol Tartrate |
| Boston Scientific Corporation | $166.69 | 2024 | Intracept |
| Merz Pharmaceuticals, LLC | $147.56 | 2022 | |
| Forte Bio-Pharma LLC | $70.38 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Valinor Pharma, LLC | $60.59 | 2023 | Movantik |
| Abbvie INC. | $51.01 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $41.99 | 2024 | |
| Nalu Medical, INC. | $41.02 | 2024 | Nalu Neurostimulation System |
| Ibsa Pharma INC. | $34.38 | 2023-2024 | Tirosint, Licart, Tirosint |
| Xeris Pharmaceuticals, INC. | $24.81 | 2023 | Keveyis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $21.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.94 | 2023 | Seglentis |
| Hikma Pharmaceuticals USA | $18.32 | 2024 | Kloxxado |
| Pfizer INC. | $17.26 | 2024 | |
| Metacel Pharmaceuticals LLC | $6.17 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.